Fisher & Paykel Healthcare Corp Ltd
The company is a New Zealand-based designer, manufacturer and a marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. These products and systems are sold in around 120 countries worldwide. Its segments include North America, Europe, Asia-Pacific and New Zealand. In homecare the company is developing its range of devices with completion of the worldwide introduction of both its F&P ICON flow generator range for the treatment of obstructive sleep apnea, the introduction of its F&P Pilairo nasal pillows mask and development of the second generation AIRVO2 humidity therapy device.
The company entered the respiratory care market in 1971 with the development of a unique respiratory humidifier system for use in critical care. It sells its products through direct sales offices operations in most of its major markets and a network of distributors that sell to hospitals, homecare providers and other manufacturers of medical devices.
In 1934 the Fisher & Paykel started its business as an importer of refrigerators, washing machines and radios. In the year of 1938 it signed an agreement with Kelvintor and in middle 1950 moved to manufacturing products using the company's own technology. The healthcare involvement started in the late 1960s. At that time F&P sought involvement in a business that could benefit from their growing manufacturing and electronic expertise. There is a prototype respiratory humidifier, developed in the country for use with patients needing ventilation in hospital intensive care situations, was taken to production by F&P.
Since the company has consistently developed innovations to improve patient care and developed world-wide distribution for the products. On November 2001, as part of reorganization, Fisher & Paykel Industries Limited was renamed as Fisher & Paykel Healthcare Corporation Limited and a new company, Fisher & Paykel Appliances Holdings Limited, was established to own F&P's appliances and finance business.
On May 23, 2013 the F&P Healthcare rose 2.6 percent to NZ$3.11, its highest since May 2011. Earlier, the company reported a 20% rise in profit to NZ$77.1 million in the year to March, exceeding company and market forecasts for NZ$75 million, and forecast profits around NZ$85 million-NZ$90 million for 2014.
On August 27, 2013 the company which makes patient warmers and products to tret breathing disorders, forecast a profit of NZ$90 million to NZ$95 million ($70.3 million to $74.2 million) for the year ended March 31, based on an exchange rate of $0.8000. it had previously forecast a profit range of NZ$85 million to NZ$90 million.
The Fisher & Paykel Healthcare Corp Ltd currently has a market capitalization of 1.99 Billion, EPS is 0.14, P/E ratio is 26.72 and the dividend yield is 3.37% at the annual dividend payout of 0.07.
The company is currently one of the best leading New Zealand dividend stocks which are performing well from past five years. Its consistent growth strategy is to provide an expanding range of innovative medical devices which can help to improve care and outcomes for patients in an increasing range of applications.